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leiomyomatosisAbstract Intravenous leiomyomatosis (IVL) is a rare tumor, characterized by benign smooth muscle
growth inside veins. The tumor arises from the uterine venouswall or uterine leiomyomas and is usually
confined to the pelvic cavity. However, on rare instances, it may extend into the cardiac cavity (Pathol
Annu 1988;23 Pt 2:153–158), and the pulmonary system (Arch Gynecol Obstet 2001;264:209–210).
Treatment consists of surgical removal of the tumor, cessation of ovarian function and avoidance of
estrogen replacement therapy (Gynecol Obstet Invest 2004;58:168–170). We present a case of
intravenous leiomyomatosis with extension from IVC to RA, RV and PA, with an unusually rapid
course of progression in the absence of estrogen (TAH-BSO, without concomitant hormonal therapy).
© 2014 TheAuthors. Published by Elsevier Inc. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
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y-nc-nd/3.0/).from within venous walls or uterine leiomyomas. Though
typically confined to the pelvic cavity, they may spread
along vessels and extend right up to the cardiac cavities,
causing significant cardiovascular symptoms [1]. First
reported in 1907 [2], IVL with cardiac extension is seen
in up to 10% of cases, and is often misdiagnosed as a
primary cardiac tumor or a venous thrombus in transit [3].
Right atrial and ventricular involvement has been reported
in 30% and 70% of cases respectively [4]. Extension orrticle under theCCBY-NC-ND license (http://creativecommons.org/licenses/
14 M.L. Kim et al.embolization into the pulmonary artery (PA) system is
very rare, and has been reported in less than 5% of
cases [5]. Thus far, there have been 11 cases of PA
extension reported in the English language literature [6].
Standard treatment consists of complete surgical removal,
with cessation of ovarian function and avoidance of post-
operative estrogen replacement therapy, as estrogen and
progesterone receptors have been detected in the nuclei of
IVL cells [7].
We present a case of IVL with cardiac involvement
with extension to the PA, with an unusually rapid course of
development in the absence of exogenous estrogen.2. Case presentation
A 58-year-old womanwas referred to our institution after
routine computed tomography (CT) of the chest, abdomen,
and pelvis for follow-up. Her history was significant for
hypertension, dyslipidemia, depression and hypothyroid-
ism. Her medications included ramipril 2.5 mg PO OD,
rosuvastatin 20 mg PO OD, levothyroxine 0.088 mg PO
OD, venlafaxine 100 mg PO OD and lamotrigene 200 mg
PO OD. She was a life-long non-smoker, and did not
consume alcohol. Her surgical history included a total
abdominal hysterectomy with bilateral salpingo-oophorec-
tomy (TAH-BSO) five years prior, for endometrial bleeding.
Pathology confirmed intravenous leiomyomatosis. She did
not receive any concomitant hormonal therapy, and was
followed with routine imaging, which was unremarkable
after three years post-surgery. Seventeen months after her
last follow-up, she underwent repeat routine CT of her
abdomen and studies, which showed new filling defects in
the main PA, right main PA, with extension into the
segmental arteries of the right lower lobe. Proximally, the
filling defect extended into her right atrium (RA) and
ventricle (RV), with extension into the inferior vena cava
(IVC) up to the level of her gonadal veins. She was
asymptomatic, and was referred for surgical management.
On examination, her blood pressure was 127/80 mmHg
and heart rate, 96 bpm. Her physical exam (abdomen, lower
limb, neurological exam) was unremarkable and laboratory
data were all within normal limits. Chest x-ray was
unremarkable, and ECG showed sinus rhythm. Transesoph-
ageal echocardiogram (TEE) revealed a highly mobile
variegated mass extending from the IVC to the RA, RV and
PA (Fig. 1). CT confirmed the findings, and demonstrated a
right adnexal mass with extension to the gonadal vein
(Fig. 2). Coronary angiography was normal and showed the
conus supplying two independent mobilemasseswith tumor
blush visible. The extensive mass was removed
via thoracotomy and laparotomy with no complications.
Post-operative TEE was normal, and she was discharged
home in stable condition.3. Pathology
The explanted gray-white and blue mass had a
variegated shape measuring 6.5 × 5.5 cm at the cardiac
end, with a narrow 55 cm tube extending from it. The mass
is nodular with no discernible capsule between the
nodules. The “tube” measured 3.0 cm in diameter at one
end, and narrows to 0.6 cm at its most distal end (Fig. 3).
Histological examination revealed a tumor composed
of cords and bundles and masses of spindle cells with
features of neoplastic smooth muscle cells with no direct
involvement of the endocardial surface of the blood
vessels or the cardiac chambers (Figs. 4–5), except at the
right atrium. Immunohistochemistry was positive for
smooth muscle cells (SMActin), consistent with intrave-
nous leiomyomatosis (Fig. 4). Staining for estrogen
receptors showed strong signaling, with 80–90% of cells
being positive, while progesterone receptor staining showed
strong positivity (70–80%). The core of the tumor as well as
the residual tumor was positive for both receptors (Fig. 6).4. Discussion
We present a 58-year-old Caucasian woman who had
uterine leiomyomatosis and was found, on serial imaging
during follow-up, to have IVL growth extending up to her
PA. She had undergone a TAH-BSO 5 years prior, for
uterine IVL which was not followed by hormone
replacement therapy (HRT).
IVL is a rare benign tumor characterized by the growth
of smooth muscle cells within the venous system. It is most
commonly seen in premenopausal women with an average
age of 44 years [1]. In the majority of cases, only the
pelvic veins are involved; however, in rare instances,
tumor growth may extend into the IVC, with cardiac
extension in up to 10% of cases [3]. Since its first
description, there have been multiple cases reported in the
English language literature. Wu et al. reviewed 77 cases of
IVL with intracardiac extension from 1900 to 2008 [8],
and since then, there has been an additional 14 cases.
These findings are summarized in Table 1.
Although the etiology of IVL is unknown, there are two
widely accepted theories on its development. Knauer [9]
hypothesized that the tumor originates from smooth
muscle cells within the vessel wall, while Sitzenfry [10]
proposed that its invasion into the veins from a uterine
source leads to IVL development. Though the pathogen-
esis has not been thoroughly studied, Fukuyama et al.
examined the mechanism of IVL development in one case,
and found extension of CD34 antibody staining from the
myoma which advanced into the lining of the vein [11].
This finding has not been replicated in other studies and its
Fig. 1 Transesophageal echocardiographic images. Two-dimensional transesophageal image showing the IVL within the right atrium
(A), and the inferior vena cava (B). The left atria (LA) and liver (L) can also be seen.
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uncertainty, the presence of estrogen and progesterone
receptors in the cell nucleus argues that the tumor is indeed
of uterine origin [12]. Our case was positive for estrogen
and progesterone receptors on histological analysis, which
argues that the tumor mass did indeed originate from the
uterine wall. Though we do not have access to the
pathological specimen from her index surgery, we
hypothesize that there were cells remaining within the
gonadal veins after her initial surgery.
Leiomyomas are most common in pre-menopausal
women and the tumors generally stabilize or regress after
menopause, due to the presence of estrogen and
progesterone receptors. Their continued growth is depen-dent on the systemic effect of circulating hormones. Their
growth and development of cell atypia have also been seen
during pregnancy and with the use of oral contraceptives
[13]. Studies have shown elevated levels of serum growth
hormone and estradiol in women with leiomyomas [14].
As a result, treatment strategies for estrogen deprivation
have been suggested, and include discontinuation of
hormonal replacement therapy, the use of anti-estrogen
or GnRH analog use, surgical excision including BSO, and
lastly, ovarian irradiation [5,15]. In our patient, she
underwent TAH-BSO, and despite the lack of exogenous
estrogen, our patient had marked growth of her IVL within
17 months, which makes this particular case so unusual.
Of the recent reported cases (Table 1), one 81-year-old
Fig. 2 Cardiac computed tomography. Coronal oblique (A) and axial (B) contrast enhanced cardiac computed tomography images with
optimal opacification of the superior vena cava (S), right atrium (A) and right ventricle (V). There is a large filling defect (arrow)
extending from the right atrium, across the tricuspid valve, into the right ventricle and the right ventricular outflow tract (T).
Fig. 3 Gross image of excised tumor mass following surgery. The tumor mass measured 6.5 × 5.5 × 3.5 cm, and narrows into a tube
which was 55 cm long, and ranges in diameter 0.2 cm at its distal end to 2.3–5.5 cm at its proximal end.
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Fig. 4 (A) Intravascular tumor (T) within the blood vessels (BV) of the myometrium (hematoxylin and eosin stain, original
magnification ×1.6). (B) Immunohistochemical staining shows bundles of smooth muscle within the tumor mass (smooth muscle actin
stain, original magnification ×20).
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uterine leiomyoma. Pathology reports suggest the tumor had
occurred from the blind end of the remnant right ovarian
vein after BSO, and the cells were highly expressive in
estrogen receptors [16]. This case is similar to ours, whereas
both patients underwent BSO, but both developed recur-
rence many years later without the predominant source of
endogenous estrogen. Though the case reported byOkada et
al. does not explicitly state if their patient was receiving
hormone replacement, these cases do suggest that despite
surgical removal of the ovaries, continued growth can occur.
Although, this is suggestive of a high serum estrogen level, it
is not clear whether or not their patient was on estrogen
replacement therapy. In post-menopausal women, endoge-
nous estrogen can still be produced by peripheral tissues
(mainly adipose and skin fibroblasts) by converting
androstendione (secreted by the adrenal cortex), intoestrone. It has been demonstrated that mRNA of aromatase
and its activity increase as a function of obesity [17] and
aging [18]. In our case she had a BMI of 29.4 kg/m2 and
abdominal obesity (waist circumference of 97 cm). Though
we do not have serum estrogen levels measured in our
patient, taking into consideration the body habitus and age of
our patient, it is possible that there was a higher than
expected level of estrogen, causing progression of IVL.
Similarly, there is evidence suggesting that estrogen
produced by adipose tissue has a critical role in breast
cancer genesis [19]. The possibility of such extra sources of
endogenous estrogen production may explain the rapid
course of IVL growth seen in our patient which is
remarkable given the characteristic minimal to absent
mitotic activity of leiomyomas.
Extension or embolization into the pulmonary system
is seen in rare occasions, and has been reported in less than
BV
Fig. 5 Intravascular tumor (T) shows a layer of endothelial cells (arrow) lining the mass, which is completely separate from the blood
vessel (BV) epithelium (arrow). Note that the tumor was completely encapsulated in endothelial cells at the proximal portion closer to the
pelvic cavity, whereas closer to the heart, the mass was surrounded by a broken layer of endothelial cells (CD31 immunohistochemical stain
for endothelial cells, original magnification ×40).
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reported in the English literature thus far [6], and reports
that describe ‘metastasis’ of IVL to the lungs and lymph
nodes [20]. In the cases of IVL with PA extension reported
thus far, 8 out of the 9 cases with clinical information had
symptoms leading to further examination and diagnosis.
This is unlike our case where the mass was incidentally
found during routine follow up. In understanding the lack
of symptoms of our patient, it is important to keep in mind
a key morphologic feature found in many IVLs – the
presence of an inner circulating lumen. This finding has
been used to support Knauer's theory that the tumor is of
vascular wall origin. Merchant et al. have identified anFig. 6 Immunohistochemical staining shows extensive amounts of estrog
(70–80% of cellular nuclei) (B) present within the tumor (estrogen (A) andunusually arrangement of vessels within the myometrium
in which an artery is found in the lumen of a dilated venous
channel. They named this finding ‘vessels within vessels’
and suggested that this may provide an anatomical basis
for the pathogenesis of IVL [21]. In the present case, the
lumen within the mass may explain how the patient was
asymptomatic despite the extent that her tumor spread.
Our case is a second occurrence of IVL with intracardiac
extension in a patient with previous TAH-BSO. She was not
put on hormonal replacement therapy post-surgery because
of concerns that estrogen may enhance IVL growth, as
previous reports have shown that IVLs are estrogen sensitive
[22]. Despite the given circumstances, she developed aen receptor (80–90% of cellular nuclei) (A) and progesterone receptor
progesterone (B) receptor staining, original magnification ×20).
Table 1 Reported patients with intracardiac leiomyomatosis from 2009 to 2012.
Authors
and reference
Year Age
(year)
Estrogen status Symptoms
at presentation
Imaging Size/location Treatment Outcome
Kim et al. 2012 58 N; TAH-BSO
5 years ago
None TEE,
CT, MRI
PA Sx Well
post op
Okada et al.
[16]
2012 81 N; TAH-BSO
30 years ago
Palpitation Echo, CT RA Sx Well at
1 year
Vural et al.
[24]
2011 48 Y Dyspnea, chest pain,
pelvic pain,
dysmenorrhea
RA Sx -
Li et al. [25] 2011 36 Y Sudden and
transient syncope
CT R heart, IVC,
common
iliac veins,
right internal
iliac vein,
fibromatosis
of uterus,
multiple cysts
in right
periovarian region
Sx -
48 Y Sudden syncope
(several times)
Type B US,
ultrasonic
cardiogram,
MRI
Pelvic cavity,
IVC, RA
Sx -
51 Y; hysterectomy
(hysteromyoma)
Recurrent
sudden syncope
MRI in/out of
RA & RV,
IVC, R iliac vein
Sx -
43 Y: partial
hysterectomy
Asymptomatic MRI R iliac veins,
IVC, RA,
Pelvic mass
Sx -
Vaideeswar
et al. [26]
2011 32 Y; partial
hysterectomy
Exertional
dyspnea (2 mo)
Echo,
CT,
Doppler
RV Sx Well at
19 mo
53 Y Progressive
breathlessness
(6 mo), palpitation,
episodic chest pain
Chest
radiography;
Echo
- Sx -
Song et al.
[27]
2011 56 Y; hysterectomy Exertional
dyspnea (1 year),
worsening dyspnea
RA Sx -
Lee et al.
[28]
2011 43 Y Palpitation, dizziness,
dyspnea, chest
pain (2 wk),
syncope (×3) on
admission day
MRI, TEE RA,
embolized
to PA
Sx Well at
2 years
Yu et al. [29] 2011 52 Y Dyspnea (10 years),
palpitation (3 mo)
Echo,
CT, US,
MRI
RV Sx Well at
2 years
49 Y Palpitation (7 mo) Echo,
CT,
Ultrasound
RV Sx Well at
6 mo
Singh et al.
[30]
2010 43 Y, hysterectomy RUQ pain, bloating
and swelling of the left leg
US,
Echo, CT
RA Sx -
Wu et al. [8] 2009 39 Y; hysterectomy Intermittent chest pain (2 mo)
progressive dyspnea (1 wk)
Chest radio;
TEE, CT
RV Sx -
Data unavailable; Y yes; N no; TAH-BSO total abdominal hysterectomy bilateral salpingo-oophorectomy; RUQ right upper quadrant; Echo
echocardiography; CT computed tomography;US ultrasound;MRImagnetic resonance imaging; TEE transesophageal echocardiography; RA right atrium;
RV right ventricle; IVC inferior vena cava; Sx surgery.
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20 M.L. Kim et al.significant mass of IVL that extended up to the PA system,
in about 17 months. As a comparison, the average interval
between hysterectomy and recurrent IVL, most of which do
not extend into the cardiac chambers let alone the PA
system, is 3.4 years [23]. This rapid course of extensive
growth despite all preventative measures taken makes this
case unique.Funding sources
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